EIF1
Eukaryotic translation initiation factor 1
Also known as: A121, EIF-1, EIF1_HUMAN, EIF1A, ISO1, SUI1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P41567
- Gene
- EIF1
- Ensembl
- ENSG00000173812
- Chromosome
- 17
- Canonical length
- 113 aa
- Protein class
- Plasma proteins, Predicted intracellular proteins
OverviewNCBI Gene
Enables ribosomal small subunit binding activity and translation initiation factor activity. Involved in regulation of translational initiation and translational initiation. Located in cytoplasm and nucleus. Part of eukaryotic 43S preinitiation complex; eukaryotic 48S preinitiation complex; and multi-eIF complex. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
113 residues, UniProt reviewed canonical sequence.
>P41567|EIF1
1 MSAIQNLHSF DPFADASKGD DLLPAGTEDY IHIRIQQRNG RKTLTTVQGI ADDYDKKKLV
61 KAFKKKFACN GTVIEHPEYG EVIQLQGDQR KNICQFLVEI GLAKDDQLKV HGFLocalizationUniProt · AlphaFold · HPA
Whether an antibody against EIF1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.42
- Highest tissue expression
- 1,182 nTPM
Expression across tissuesHPA
Tissue
- skeletal muscle: 1,182 nTPM
- bone marrow: 712 nTPM
- blood vessel: 466 nTPM
- heart muscle: 463 nTPM
- adipose tissue: 459 nTPM
- pancreas: 456 nTPM
Single-cell type
- esophageal apical cells: 15,382 nCPM
- late spermatids: 10,962 nCPM
- syncytiotrophoblasts: 5,022 nCPM
- esophageal suprabasal cells: 4,944 nCPM
- pancreatic acinar cells: 4,157 nCPM
- decidual stromal cells: 3,771 nCPM
Immune cell
- basophil: 1,148 nTPM
- total PBMC: 592 nTPM
- eosinophil: 465 nTPM
- non-classical monocyte: 458 nTPM
- intermediate monocyte: 440 nTPM
- T-reg: 430 nTPM
Brain region
- white matter: 481 nTPM
- medulla oblongata: 443 nTPM
- cerebellum: 423 nTPM
- basal ganglia: 415 nTPM
- pons: 413 nTPM
- hypothalamus: 404 nTPM
ReferencesPubMed · IEDB
Publications for EIF1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
3 publications
- Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma.
2010 · Cancer Lett · RCR 1.3 · 44 citations - Autoantibody response to Sui1 and its tissue-specific expression in hepatocellular carcinoma.
2016 · Tumour Biol · RCR 0.3 · 8 citations - Six autoantibodies as potential differential biomarkers of hepatocellular carcinoma vs. liver cirrhosis and chronic hepatitis: A prospective multi-institutional study.
2022 · Oncol Lett · RCR 0.2 · 2 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.51
- gnomAD pLI
- 0.83
- gnomAD missense Z
- 1.87
- DepMap mean gene effect
- -1.14
- DepMap dependency class
- common
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- ribosomal small subunit binding
- RNA binding
- translation factor activity, RNA binding
- translation initiation factor activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of EIF1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads EIF1 as an antibody target. Whether an autoantibody or antibody against EIF1 could matter depends on whether native EIF1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
EIF1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label EIF1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...